Finnland - Medizinische Ausrüstung, Arzneimittel und Produkte der Körperpflege - Informationsanfrage: NGS-Tests für die Genotypisierung des Hepatitis-C-Virus

With this request for information, Helsinki University Hospital (HUS, Helsinki, Finland) launches a market consultation to prepare a procurement. The aim of this prior information notice is to find suppliers operating in this field of business, get information of the solutions available in the market, and inform our plans and requirements for the forthcoming procurement. SUBJECT OF THE PROCUREMENT Test intended for the genotyping of the Hepatitis C virus (HCV) based on NGS (next-generation sequencing) technology. Requirements for the test: The test must be able to identify HCV genotypes 1-8 and their subtypes. The test must be compatible with plasma and serum samples. The test must include sequencing analysis software. We kindly request that, should your product range include an item matching the subject of the procurement, you respond to the following questions QUESTIONS FOR SUPPLIERS 1. Please provide a list of the products in your range that are suitable for the above-mentioned application. 2. Are the test and the sequencing analysis software CE-IVD marked? 3. Which NGS sequencing platforms are compatible with the test? 4. Which HCV genes does the test identify and differentiate? 5. Does the test include internal quality control (controls)? If yes, please list the controls. 6. What is the price/price range of the test? 7. What is the promised shelf life of the test components? 8. What equipment is required to perform the test? 9. With 1 unit of your product, how many patient samples can you process? (For example, a kit unit for 24 samples but 3 controls need to be included in a run > 1 unit is sufficient for 21 patient samples) 10. Please describe the analysis software included with the test (cloud-based/local analysis, data storage capability, user account restrictions, etc.). 11. What is the delivery time for the test? 12. Is there a Finnish distributor for the test? 13. Is there a support service available in case of issues? 14. Contact details for potential market dialogue We kindly request that respondents provide also a method brochure and kit inserts. INSTRUCTIONS FOR ANSWERING Answers to questions should be submitted by 2nd of October 2025 at the latest to the email address: kilpailutus.diagnostiikka@hus.fi The title or message field of the e-mail should mention: "Answer to HUS 328-2025 HCV sequencing". INFORMATION FOR THE PROCEDURE HUS is tentatively planning to publish a call for tenders autumn 2025. This notice is not a call for tenders. HUS may specify the subject of the procurement in a subsequent contract notice. The requirements for a subsequent procurement and invitation to tender will be determined on the basis of the needs of the contracting entity, with the aim of taking into account the information obtained in the market survey. This notice provides the information currently held by the contracting entity on the procurement to operators on the market. The procurement is in the planning stage and the plans, with their schedules and information, can still be specified and changed. The request for information does not oblige the procurement unit to carry out the actual procurement, but the decision to initiate a possible procurement process is made separately. Neither the request for information nor its replies are binding on either party. Responding to a request for information does not affect the position of the tenderer in the forthcoming tender. The costs associated with responding to a request for information are borne by the respondent, and HUS does not pay compensation for responding to a request for information or participating the procurement procedure.